Cibus (CBUS) AI Stock Analysis

• Market Cap: $155.52M
• Dividend Yield: N/A
• Average Volume (3M): 154.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.00
• Revenue Growth: -8.64%
• EPS Growth: 85.68%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 66,040,960
• 10 Day Avg. Volume: 164,630
• 30 Day Avg. Volume: 154,044
• PEG Ratio: <0.01
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 15.15
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 34.60
• Enterprise Value/Gross Profit: 54.70
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $18.67
• Price Target Upside: 711.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $2.00 ▼(-13.04% Downside)

Score is held back primarily by weak financial performance (losses, declining revenue, and negative cash flows) and a short cash runway highlighted on the earnings call. Technicals are moderately supportive with price above key moving averages, while valuation is constrained by negative earnings and no dividend.

Positive Factors

Commercial Partnerships - Rice Traits

Securing seven partner agreements across 5–7M acres creates a durable commercialization pathway. Large addressable acreage and partner-led sales shift go-to-market risk to licensees, supporting scalable, royalty-based revenue streams once traits launch (2027–2030).

Product Diversification - Biofragrance

Pre-commercial pilots for biofragrances establish a non-seed revenue stream with earlier commercial cadence. Yeast fermentation products can provide recurring product sales and milestone payments, diversifying cash generation and reducing sole reliance on trait regulatory timelines.

Operational Cost Reductions

Meaningful opex cuts and consolidation improve capital efficiency and extend runway. A lower cash burn target increases flexibility to fund core commercialization, prioritize high-return programs, and makes future financing needs smaller or more strategic over the medium term.

Negative Factors

Negative Cash Flow

Persistent negative operating and free cash flows mean the business cannot self-fund R&D and commercialization. Over 2–6 months this structural cash deficit increases dependency on external financing, risking dilution or program delays if capital markets tighten.

Very Low Recent Revenue

A sub-$1M quarterly revenue run-rate reflects limited current commercial traction and high revenue volatility. This low baseline reduces internal funding capacity and highlights reliance on milestone payments and future royalties to drive sustainable top-line growth.

Tight Cash Runway

With cash expected to cover operations into early Q2 2026, the company faces an imminent financing imperative. Even with cost cuts, this timing pressure can force hurried capital raises, potential dilution, or deferred commercialization steps, constraining execution risk over the next months.

Cibus Business Overview & Revenue Model

Company Description

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

How the Company Makes Money

Cibus generates revenue primarily through the licensing of its proprietary gene-editing technology and the sale of its gene-edited crop products. The company partners with agricultural firms and seed companies to develop and commercialize its products, allowing it to earn royalties on sales made by its partners. Additionally, Cibus may engage in strategic collaborations or joint ventures that provide upfront payments or milestone payments based on the achievement of specific development goals. The company’s focus on innovative agricultural solutions positions it to benefit from increasing demand for sustainable agricultural practices, further contributing to its revenue streams.

Cibus Financial Statement Overview

Summary

Weak fundamentals driven by persistent losses, declining/volatile revenue, and negative operating/free cash flow. Balance sheet leverage appears manageable, but negative ROE and limited equity buffer elevate financial risk.

Income Statement

Cibus has experienced significant revenue volatility, with a notable decline in TTM revenue growth. The company shows negative net profit and EBIT margins, indicating ongoing profitability challenges. Despite a high gross profit margin, the overall financial performance is weak due to substantial losses.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. However, the negative return on equity indicates that the company is not generating returns for shareholders. The equity ratio is relatively low, reflecting a limited buffer against liabilities.

Cash Flow

Cibus's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. The company struggles to generate positive cash flow, posing a risk to financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.79M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	2.40M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-85.62M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-118.90M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	330.23M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	23.89M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	33.95M	36.29M	24.62M	13.91M	17.88M	19.76M
Total Liabilities	278.20M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	50.40M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-51.71M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-51.17M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-548.00K	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	46.80M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.73, and above the 200-day MA of 1.68, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 65.67 is Neutral, neither overbought nor oversold. The STOCH value of 92.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	57 Neutral	$114.24M	-1.56	-49.78%	―	-82.16%	14.58%
XFOR	52 Neutral	$336.63M	-0.38	-156.87%	―	2925.73%	-294.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OKYO	51 Neutral	$73.72M	-15.63	―	―	―	―
CBUS	49 Neutral	$155.52M	-0.71	-149.99%	―	-8.64%	85.68%
CRVO	45 Neutral	$43.21M	-1.61	-71.42%	―	-38.81%	-76.96%
ABVC	44 Neutral	$46.17M	-8.52	-40.32%	―	56.52%	75.22%

Cibus Corporate Events

Cibus Announces Underwritten Public Offering of Common Stock

On January 29, 2026, Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for an underwritten public offering of 13,333,333 shares of its Class A common stock at $1.50 per share, with company board members participating for 1,000,000 shares at the offering price and a 30-day option granted to the underwriter to purchase up to an additional 1,999,999 shares. The deal, expected to close on or about January 30, 2026 subject to customary conditions, is projected to raise approximately $17.8 million in net proceeds, or $20.5 million if the overallotment option is fully exercised, and includes standard indemnification, a 60-day lock-up agreement for the company and its leadership, and a 6.25% underwriting discount plus reimbursement of the underwriter’s documented expenses, underscoring Cibus’s continued reliance on equity markets to secure funding while temporarily restricting insider share sales.

The most recent analyst rating on (CBUS) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus streamlines operations to focus on rice traits

In 2025, Cibus undertook a significant operational streamlining to concentrate capital and resources on commercializing its weed management traits for rice, including a workforce reduction of about 34 employees approved in July 2025 and completed by year-end, consolidation of core operations in San Diego, and deferral of non-partner-funded non-rice activities. Management estimates its rice herbicide tolerance traits could ultimately generate more than $200 million in annual royalties across initial target markets in Latin America and the United States, while its sustainable ingredients initiatives—particularly a yeast fermentation biofragrance program that began generating nominal payments in 2025—could reach $20–40 million in annual revenue over the long term; combined with cost-cutting measures expected to lower annual net cash usage to about $30 million or less in 2026, these moves aim to bolster financial stability while preserving upside from a broader trait portfolio that Cibus plans to advance opportunistically through partner-funded projects.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus executes minor internal Class A share repurchase

On December 31, 2025, Cibus, Inc. repurchased 60,088 shares of its Class A common stock from employee Anthony Moran at a nominal price of $0.0001 per share, under a share purchase agreement approved by the board of directors. The transaction represents a small, board-sanctioned internal equity reallocation involving an employee shareholder, with limited apparent impact on the company’s broader capital structure or external stakeholders.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Appoints Craig Wichner to Board of Directors

On November 5, 2025, Cibus, Inc. appointed Craig Wichner to its Board of Directors and its Strategy Committee. Wichner, founder of Farmland LP, brings extensive experience in organic and regenerative farmland management. His appointment is expected to enhance Cibus’s strategic operations, given his background in sustainable growth and investment management. The company has entered into a standard indemnification agreement with Wichner and will compensate him with a cash retainer and equity compensation for his board service.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.